Marco Dollinger1, Ernst-Michael Jung2, Lukas Beyer2, Christoph Niessen2, Fabian Scheer3, René Müller-Wille2, Christian Stroszczynski2, Philipp Wiggermann2. 1. Department of Radiology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93042 Regensburg, Germany.. Electronic address: marco.dollinger@ukr.de. 2. Department of Radiology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93042 Regensburg, Germany. 3. Institute of Diagnostic and Interventional Radiology, Westküstenklinikum Heide, Heide, Germany.
Abstract
PURPOSE: To describe findings on contrast-enhanced computed tomography (CT) images of malignant hepatic tumors 24-72 hours after percutaneous ablation by irreversible electroporation (IRE) and at midterm follow-up. MATERIALS AND METHODS: Retrospective analysis of 52 malignant liver tumors-30 primary hepatic tumors and 22 hepatic metastases-in 34 patients (28 men and 6 women, mean age 64 y) treated by IRE ablation was performed. Ablation zones were evaluated by two examiners in a consensus reading by means of a dual-phase CT scan (consisting of a hepatic arterial and portal venous phase) performed 24-72 hours after IRE ablation and at follow-up. RESULTS: During the portal venous phase, ablation zones either were homogeneously hypoattenuating (n = 36) or contained heterogeneously isoattenuating or hyperattenuating (n = 16) foci, or both, in a hypoattenuating area. Of 52 lesions, 38 included gas pockets. Peripheral contrast enhancement of the ablation defect was evident in 23 tumors during the arterial phase and in 36 tumors during the portal venous phase. Four tumors showed intralesional abscesses after the intervention. At follow-up (mean, 4.7 mo), the mean volume of the ablation defects was reduced to 29% of their initial value. CONCLUSIONS: Because normal findings on contrast-enhanced CT images after IRE ablation may be very similar to the typical characteristics of potential complications following ablation, such as liver abscesses, CT scans must be carefully analyzed to distinguish normal results after intervention from complications requiring further treatment.
PURPOSE: To describe findings on contrast-enhanced computed tomography (CT) images of malignant hepatic tumors 24-72 hours after percutaneous ablation by irreversible electroporation (IRE) and at midterm follow-up. MATERIALS AND METHODS: Retrospective analysis of 52 malignant liver tumors-30 primary hepatic tumors and 22 hepatic metastases-in 34 patients (28 men and 6 women, mean age 64 y) treated by IRE ablation was performed. Ablation zones were evaluated by two examiners in a consensus reading by means of a dual-phase CT scan (consisting of a hepatic arterial and portal venous phase) performed 24-72 hours after IRE ablation and at follow-up. RESULTS: During the portal venous phase, ablation zones either were homogeneously hypoattenuating (n = 36) or contained heterogeneously isoattenuating or hyperattenuating (n = 16) foci, or both, in a hypoattenuating area. Of 52 lesions, 38 included gas pockets. Peripheral contrast enhancement of the ablation defect was evident in 23 tumors during the arterial phase and in 36 tumors during the portal venous phase. Four tumors showed intralesional abscesses after the intervention. At follow-up (mean, 4.7 mo), the mean volume of the ablation defects was reduced to 29% of their initial value. CONCLUSIONS: Because normal findings on contrast-enhanced CT images after IRE ablation may be very similar to the typical characteristics of potential complications following ablation, such as liver abscesses, CT scans must be carefully analyzed to distinguish normal results after intervention from complications requiring further treatment.
Authors: Judit Boda-Heggemann; Anika Jahnke; Mark K H Chan; Leila S Ghaderi Ardekani; Peter Hunold; Jost Philipp Schäfer; Stefan Huttenlocher; Stefan Wurster; Dirk Rades; Guido Hildebrandt; Frank Lohr; Jürgen Dunst; Frederik Wenz; Oliver Blanck Journal: Strahlenther Onkol Date: 2018-02-05 Impact factor: 3.621
Authors: Andreas Ritter; Philipp Bruners; Peter Isfort; Alexandra Barabasch; Joachim Pfeffer; Jula Schmitz; Federico Pedersoli; Martin Baumann Journal: Technol Cancer Res Treat Date: 2018-01-01
Authors: Laurien G P H Vroomen; Hester J Scheffer; Marleen C A M Melenhorst; Marcus C de Jong; Janneke E van den Bergh; Cornelis van Kuijk; Foke van Delft; Geert Kazemier; Martijn R Meijerink Journal: Eur Radiol Date: 2016-09-22 Impact factor: 5.315